Trials / Not Yet Recruiting
Not Yet RecruitingNCT07181239
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
A Phase III, Randomized, Open-Label, Multicenter Study Comparing CM336 Monotherapy vs. Investigators Selected Standard of Care in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received ≥2 Prior Lines of Therapy
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 280 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CM336 Injection | Specified dose on specified days |
| DRUG | Standard Of Care( SOC) | Specified dose on specified days |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2027-09-01
- Completion
- 2030-04-01
- First posted
- 2025-09-18
- Last updated
- 2025-09-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07181239. Inclusion in this directory is not an endorsement.